HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Status:
Recruiting
Trial end date:
2023-07-28
Target enrollment:
Participant gender:
Summary
Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic
agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar
cholangiocarcinoma. Based on the potential synergistic effect of bevacizumab, chemotherapy
and PD-1 inhibitor, this phase II clinical study want to test the efficacy and safety using
intra-arterial infusion of oxaliplatin, 5-fluorouracil and bevacizumab combined with
intravenous infusion of PD-1 inhibitor (Toripalimab) in the treatment of unresectable biliary
malignant tumors.